Indivior and Virginia Commonwealth University School of Pharmacy Enter Academic Partnership on Pharmacoeconomics and Health Outcomes Research

Two-year postdoctoral fellowship program at School of Pharmacy to prepare individuals for careers in PEOR field

Richmond, VA, March 2, 2017 – Indivior PLC and Virginia Commonwealth University School of Pharmacy have formed an academic partnership in the field of pharmacoeconomics and health outcomes research (PEOR). There is a growing need for PEOR expertise in the pharmaceutical industry. Patients must continue to have appropriate access to the medicines they need as payers increasingly ask pharmaceutical companies to demonstrate the value of their products.

A two-year postdoctoral fellowship program at VCU’s School of Pharmacy will provide an effective way to prepare individuals for PEOR careers in industry, academia, and government.

“We are pleased to partner with Indivior on this new fellowship program,” said School of Pharmacy Dean Joseph T. DiPiro, Pharm.D. “The combination of academic training and involvement in specific research projects provides a great opportunity for postdoctoral candidates who are interested in the growing field of pharmacoeconomics and health outcomes research.”

The fellowship will provide the opportunity to work in both an academic and pharmaceutical industry setting. The fellow will spend the majority of the first year at VCU and the majority of the second year at Indivior. The overall goal is to provide a two-year continuum where the fellow can engage in applied PEOR research.

“Indivior is committed to advancing insights in pharmacoeconomics and health outcomes, which are key to demonstrating the value of medical therapies to patients, physicians, and payers, and can drive new meaningful innovation for the marketplace,” said Susan Learned, M.D., Pharm.D., Ph.D., Senior Vice President, Global Clinical Development at Indivior. “We have a longstanding relationship with VCU and are proud to support this fellowship program in partnership with the School of Pharmacy.”

Applicants for the fellowship program should have an interest in managed care, health economics, outcomes research, health policy, addiction medicine, substance abuse research or related fields, and should have a doctoral degree (M.D., Pharm.D. or Ph.D.) in a health-related discipline.

VCU and Indivior envision bringing in one new fellow each year. The VCU School of Pharmacy is actively soliciting applications for the first fellow, whose planned start is July 2017. Visit https://www.vcujobs.com/postings/59162 for additional information and application instructions.

About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global opioid dependence portfolio, Indivior has a strong pipeline of product candidates designed to expand treatment options in opioid use disorder, alcohol use disorder, cocaine intoxication and
About VCU School of Pharmacy
Rated among the nation's top professional graduate programs, Virginia Commonwealth University School of Pharmacy is at the scientific forefront in pharmacotherapy and outcomes science, pharmaceutics and medicinal chemistry education, experiential education, research and community engagement. Founded in 1898, the school has a long history of pioneering changes in the field of pharmacy and offers the most comprehensive selection of pharmacy-related degree programs and postdoctoral opportunities in Virginia. Pharmacy practice has changed dramatically, now serving as a primary information resource in drug management for patients and as an integral part of the health-care team. For more, visit www.pharmacy.vcu.edu.

Media Contacts

Indivior
IndiviorMediaContacts@indivor.com
Phone: +1 804-594-0836

Cynthia McMullen
VCU School of Pharmacy
Office of Public Relations and Communications
(804) 828-6470

schizophrenia. Headquartered in the United States in Richmond, Virginia, Indivior employs more than 900 individuals globally and its portfolio is available in over 40 countries worldwide. Its name is a fusion of the words individual and endeavor and its logo radiates the company’s patient-centered holistic focus on expanding access to high-quality treatment services for addiction worldwide. For more information, please visit www.Indivior.com.